Abstract
all age groups and especially in women and high risk people. After age matching, mortality rate of diabetic patients is thought to be 1.5 to 2.5 times more than general population (2) . Overweight and obesity are major causes of DM and insulin resistance; as in most of the cases, insulin resistance and DM are accompanied by obesity (3) . Adipose tissue is not only responsible for energy storage by triglycerides but also involved in hormone secretion such as leptin, adiponectin and visfatin and could stimulate insulin signals. The adipose tissue indeed is an endocrine tissue and secretes adipokines which their direct and indirect effects on lipid and glucose metabolism have been recognized. These factors could also increase insulin resistance while some others like adiponectin decrease insulin resistance and have protective effects against development of type II DM (4) . It has been demonstrated that omega-3 fatty acids can decrease blood triglycerides and cholesterol, relieve inflammation, decline prevalence of cardiovascular diseases and cancers and prevent insulin resistance (5). They switch off the genes involved in lipid synthesis, decrease the hormones associated with obesity such as insulin and leptin; and inhibit omega-6 fatty acids production (5). Shah and colleagues reported that administration of omega-3 fatty acids could decrease triglyceride levels and improve the effects of insulin in type II DM patients without any reduction of blood glucose (6). Friedberg and his colleagues reported that administration of omega-3 fatty acids in DM patients was not effectual on HbA1C level but triglyceride level was decreased 30% and concluded that omega-3 fatty acids are beneficial in treatment of lipid disorders in DM patients (7) . Administration of more than 4 grams of Eicosapentaenoic acid (EPA) or Docosahexaenoic acid (DHA) increases serum glucose and decreases triglyceride level (8) . Kazemi and his colleagues' study demonstrated that administration of cucurbit powder in diabetic rats would improve lipid profile and reduce inflammatory factors (9) . Visfatin is a novel adipokine which was detected in visceral fat by Fukuhara and colleagues in the year 2005 (10) . It is mostly secreted from visceral adipose tissue (11 and 12) and has insulin-like functions (11) (12) (13) . Moreover visfatin has a regulatory role in metabolism of lipids (14) and has a direct relationship with body mass index (15) . Meanwhile serum visfatin level is higher in DM patients compared to normal population and has a direct relationship with waist-hip ratio (WHR) (12) . There are contradictory reports about correlation between visfatin and amount of visceral fat mass, amount of adipose tissue, type II DM and body mass index (11 and 12) . Correlation studies have demonstrated the relation between circulating visfatin level and serum triglyceride level but there have not been any correlation between serum visfatin level and fasting blood sugar, insulin resistance and beta-cells functions. Sun and colleagues demonstrated that overeating and obesity could significantly decrease circulating visfatin level (14) . While circulating visfatin level is not associated with total body obesity it has a direct relationship with HDL-c level and an inverse relationship with serum triglyceride level. These results reveal the beneficial effects of visfatin on lipid profile of non-DM patients (16) . In a study serum visfatin levels in type II DM patients and normal population were evaluated and revealed that after matching of variables such as age, sex and type II DM, there was a strong relationship between serum visfatin level and abdominal obesity. This study also evidenced insulin-like functions of visfatin as well as its association with increased insulin sensitivity, HWR and metabolic disorders (17) . Regarding these evidences and similarity of functions of visfatin and insulin, we designed and conducted this study to evaluate the effect of administration of omega-3 fatty acids on serum visfatin level.
Material and Methods:
This study was a double blind randomized clinical trial on women with type II DM aged 45-65 years who came to Isfahan diabetes charity center. Utilizing sample size estimation formula along with considering 15% additional samples, sample size was determined to be 39 in each group. Eventually the study came to an end with 37 individuals in omega-3 group and 34 ones in placebo group. Women with type II DM with a minimum 5 years documented history of DM were offered to take part in the study. Inclusion criteria were DM patients not receiving insulin and without secondary complications of DM comprising ophthalmological, renal and cardiovascular complications, limb amputation and inflammatory diseases or CRP more than +++. Individuals were involved in the study after taking informed consent and approval of ethics committee of Tehran University of Medical Science. Individuals were randomly divided into the omega-3 group and the placebo group. The intervention group received two capsules of omega-3 every day. Each capsule contained 1000 mg omega-3, 65% EPA (360 mg) and 35% DHA (240 mg). The placebo group received two capsules of placebo containing one gram of corn starch. The study was consisted of three phases. In the first phase, information about individuals' age, height, weight, and also waist and hip circumferences were collected and entered in a questionnaire and then blood sampling was done. The second phase was the intervention phase which lasted for 8 weeks and afterwards data about individuals' weight and waist and hip circumferences were collected again and another blood sampling was performed. Hip circumference was measured at the largest part of hip and waist circumference was measured at umbilical level after a common expiration. Levels of sugar, HbA1C and lipid profile (LDL, HDL, cholesterol) of blood samples were measured by Pars Azmoun Corporation Kit and visfatin by ELISA with human visfatin kit from Adipogene Corporation (Korea) with sensitivity of 30 pg/ml. During the tests, laboratory staff and patients were unaware of the intervention. Blood samplings were performed after 10 to 12 hours of fasting and before administration of hypoglycemic drugs through collecting 10 milliliters of individuals' blood by an educated technician. Of this amount, 2 ml was stored in the Vacuette test tube which contained K 3 EDTA and used for measurement of HbA1c and the remainder was stored in specific test tubes which contained nitrogen. Blood samples were centrifuged at 3000 g for 10 minutes; serum was isolated and stored at freezer at -80°C till the time for measurement of fasting blood sugar and visfatin, CRP and lipid profile. All tests were performed by Hitachi 911 device automatically and results were analyzed by SPSS software version 18. Qualitative and quantitative variables were analyzed with Fisher's exact test and Student's t-test respectively. We used Chi square test for analysis of individuals' weight changes and Pearson's correlation test to determine the correlation between variables. We also used Paired Samples T Test to compare visfatin levels before and after intervention in each group and Independent T-Test to compare mean visfatin level changes between two groups.
Results:
There was no difference in demographic variables including age, sex, education level and individuals' jobs between the omega-3 and placebo groups. There was neither any difference in other variables including history of comorbidities, administration of medications and patients' diet; thus there wasn't any confounding effect related to these variables. Mean age of the patients in omega-3 and placebo groups was 53.6 ± 4.3 and 53.9 ± 5.4 years respectively which was not significantly different between two groups (p=0.79). Data about body mass index, serum level of visfatin, weight, waist and hip circumferences, WHR, blood sugar and HbA1c is depicted in table 1. Although body mass indices were not significantly different before and after intervention in each group but mean changes of body mass indices were different between two groups. We also found same results about individuals' weight, waist and hip circumferences as well as WHR. Serum visfatin level before intervention was not significantly different between two groups (p=0.14). While serum visfatin level in omega-3 group was significantly different after the intervention (P<0.001), it remained invariable in the placebo group (P>0.05). In addition to that, difference of mean changes in serum visfatin levels of omega-3 and placebo groups before and after intervention was statistically significant. We didn't notice any significant difference in fasting blood sugar before and after intervention in each group. There was also no significant difference in changes of fasting blood sugar before and after intervention between two groups (P>0.005). While HbA1c levels of the omega-3 and placebo groups were not different before (P=0.8) and after intervention (P=0.09), mean change of HbA1c levels before and after intervention was significantly different between two groups of the study (P=0.003). Results of this study demonstrated that administration of omega-3 fatty acids could decrease patients' weight. Weight of the patients in the placebo group was decreased during intervention and weight changes were significantly different between the groups (figure 1).
Discussion:
Aim of this study was to evaluate the effect of omega-3 fatty acids on serum visfatin levels in patients with type II DM. Regarding results of this study administration of omega-3 fatty acids is beneficial in overweight prevention. We also found that administration of omega-3 fatty acids might increase visfatin level. Mechanism of increased visfatin level following administration of omega-3 fatty acids could be increased aggregation and earlier differentiation of adipocytes which result in augmented synthesis and secretion of visfatin (18) . Tanaka and colleagues reported that visfatin is secreted from 3T3-L1 adipocytes through endoplasmic reticulum-Golgi or microvesicules (19) . Another study reported that hyperglycemia results in increased visfatin synthesis in cultured adipocytes (20) . Concerning inconsistent reports, the exact biologic functions of visfatin in pathogenesis of type II DM are not well determined. Consistent with Fukuhara and colleagues and Chen's reports (11 and 12) and unlike results of Bemdt and colleagues and some preceding studies (21 and 22), we found a direct relationship between abdominal obesity and serum visfatin level in patients with type II DM. Besides, in tandem with Bemdt and his colleagues and some other studies we found a relationship between serum visfatin level and body mass index (10-11 and 21,23) . Contradictorily Pagano and colleagues studied on obese non-DM patients and Samara and colleagues studied on non-DM patients with different weights and both found an inverse relationship between body mass index and serum visfatin level (20 and 24) . Meanwhile Chen and his colleagues studied on patients with type II DM and reported that there was no relationship between their body mass index and serum visfatin level (12). (26) . Based on these evidences there must be a relationship between serum visfatin level and various factors related to metabolic syndrome comprising insulin sensitivity, fasting blood sugar and fasting blood insulin. Preceding studies have shown that administration of omega-3 fatty acids increases fat consumption in the body and also elevates metabolism which lead to weight decrease in patients (5). Body mass index was also decreased in patients receiving omega-3 and increased in the placebo group.
Conclusion:
In our study WHR was decreased in omega-3 group and increased in placebo group. Thus administration of omega-3 fatty acids could be beneficial in weight control in DM patients. Unlike previous studies (27 and 28) in our study fasting blood sugar had been increased in both groups. It demonstrates that omega-3 administration is effectual on HbA1c level which is an index for evaluation of blood glucose control quality. This is in tandem with some previous studies but in contrast with results of Fukino and colleagues (27-28 and 29) . Unlike preceding reports about the inverse relationship between circulating visfatin level and fasting blood glucose (10-11 and 30) in our study the relationship between visfatin and fasting blood glucose was not statistically significant but there was a direct relationship between visfatin level and changes of fasting blood glucose in both groups. Comparable to insulin, visfatin could increase glucose uptake by adipocytes and muscular cells and decrease fasting glucose production in liver (11) . At the end, based on the results about the effects of omega-3 fatty acids on serum visfatin level and similar functions of visfatin and insulin and due to beneficial effects of omega-3 in other studies we recommend to include omega-3 fatty acids in high risk individuals and DM patients' diet.
